Cinnarizine + DomperidoneThird Party Manufacturing in India

Cinnarizine + Domperidone works by targeting both the vestibular cause and the visceral reflex symptoms of balance disorders. Cinnarizine blocks cellular calcium entry into vestibular sensory cells to quiet down erratic labyrinthine firing, while domperidone acts as a selective peripheral dopamine D2-receptor antagonist at the chemoreceptor trigger zone. It inhibits upper gastrointestinal stasis to help the body accelerate gastric emptying and terminate severe nausea and vomiting waves. Unlike plain anti-vertigo therapies, it stops concurrent motion-induced gastric distress. It is highly effective and well-tolerated.

Therapeutic Uses

• Refractory Vertigo: Controls disabling vertigo episodes accompanied by intense autonomic symptoms like nausea and retching.
• Advanced Motion Sickness: Prevents kinetic travel sickness in patients requiring dual neurological and gastrointestinal blockade.

Why Manufacturers Choose This Combination

Cinnarizine + Domperidone third party manufacturing in India represents a highly competitive specialty formulation offering high market advantages. Our partner facilities coordinate precision multi-component processing lines inside full WHO-GMP certified cleanrooms to maintain consistent disintegration metrics for both ingredients. Standardized raw sourcing indexed to CAS 298-57-7 ensures outstanding shelf-life and clinical efficacy.